Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Novel PARP inhibitors prepared and tested at Pfizer

Feb. 4, 2004

Department of Defense award for vaccine technology development at Generex

Feb. 3, 2004

Photodynamic therapy in combination with DMXAA shows promising therapeutic advantages

Feb. 3, 2004

Pfizer team presents novel GnRH antagonists in a recent patent

Feb. 3, 2004

Merck presents novel KSP inhibitors with utility in cancer therapy

Feb. 3, 2004

Cerus acquires mesothelin rights from Johns Hopkins University

Feb. 2, 2004

New phase I trial for RSR-13 in locally advanced NSCLC

Feb. 2, 2004

Bevacizumab inhibits tumor vascularity

Feb. 2, 2004

Exelixis scientists present new antiangiogenic ADAM-10 inhibitors

Feb. 2, 2004

Antitumor effects reported for erlotinib in metastatic head and neck cancer

Feb. 2, 2004

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...